A team built to translate HSPC engineering into therapies.
Founder-led, with a scientific advisory board and clinical collaborators across pediatric transplant, immune tolerance, cell-therapy manufacturing and hemoglobinopathies.
Mohsen Khosravi-Maharlooei, MD, MSc
HSPC engineering, immune tolerance and translational cell therapy.
Former faculty / scientist: Mayo Clinic · Columbia University
Sajid Mahmood, PhD
Cell & gene therapy, translational research, in vivo engineering.
Former Scientist, Fate Therapeutics
Banafsheh Sanjari, MSc
Operations and execution across the platform's programs.
Ali Rahnama, JD, LLM
Legal strategy, intellectual property and corporate matters.
Jalil Hakimi, MBA
Corporate strategy, business development and partnering.
Advisory and per-program collaborator relationships spanning pediatric HSCT, immunoengineering, immune tolerance, islet transplantation, manufacturing and IBD.
Chiara Cugno, MD
Pediatric HSCT & hemoglobinopathies
Fabiana Perna, MD, PhD
Cell therapy, HSCT & immunoengineering
Jorge Mansilla-Soto, PhD
Molecular immunology & cell engineering
Remi Creusot, PhD
Immune tolerance & type 1 diabetes
Audrey Parent, PhD
Stem-cell-derived islet transplantation
Michael Keller, MD
Pediatric HSCT & cellular immunotherapy
Patrick Hanley, PhD
Cell & gene therapy manufacturing
Louis Cohen, MD
Inflammatory bowel disease
Building the ecosystem a banked product needs.
Sidra Medicine (Qatar)
Lonza
All listed advisors have agreed to serve; formal advisory agreements are being finalized. Institutional affiliations are shown for identification only and do not imply institutional endorsement of Hemavive. HJF / AFRRI is an active collaboration. Miltenyi Biotec, Lonza and Children's National are ongoing discussions or advisory relationships — not signed partnerships.